A citation-based method for searching scientific literature

Lili Liu, Zhuo Shao, Ying Xia, Jiabi Qin, Yang Xiao, Zhiguang Zhou, Zubing Mei. Endocr Connect 2019
Times Cited: 6







List of co-cited articles
19 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
106
66

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
190
66


Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
110
50

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
77
50

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
95
50

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
96
50

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
100
50

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial.
John R Petrie, Nishi Chaturvedi, Ian Ford, Martijn C G J Brouwers, Nicola Greenlaw, Therese Tillin, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E K Klein,[...]. Lancet Diabetes Endocrinol 2017
134
50

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
87
33





The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis.
Heming Guo, Chen Fang, Yun Huang, Yufang Pei, Linqi Chen, Ji Hu. Diabetes Res Clin Pract 2016
33
33

Altered Patterns of Early Metabolic Decompensation in Type 1 Diabetes During Treatment with a SGLT2 Inhibitor: An Insulin Pump Suspension Study.
Neha S Patel, Michelle A Van Name, Eda Cengiz, Lori R Carria, Stuart A Weinzimer, William V Tamborlane, Jennifer L Sherr. Diabetes Technol Ther 2017
18
33

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.
John M Lachin, Saul Genuth, Patricia Cleary, Matthew D Davis, David M Nathan. N Engl J Med 2000
33

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
147
33

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
71
33

Renal effects of glucagon-like peptide in rats.
Carol Moreno, Mahesh Mistry, Richard J Roman. Eur J Pharmacol 2002
79
16

Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule.
Adriana Castello Costa Girardi, Lívia Emy Fukuda, Luciana Venturini Rossoni, Gerhard Malnic, Nancy Amaral Rebouças. Am J Physiol Renal Physiol 2008
75
16


The physiological role of glucagon-like peptide-1 in the regulation of renal function.
Lívia X S Farah, Vanessa Valentini, Thaissa D Pessoa, Gerhard Malnic, Alicia A McDonough, Adriana C C Girardi. Am J Physiol Renal Physiol 2016
51
16


DPP4 in Diabetes.
Diana Röhrborn, Nina Wronkowitz, Juergen Eckel. Front Immunol 2015
171
16

PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION.
H ELRICK, L STIMMLER, C J HLAD, Y ARAI. J Clin Endocrinol Metab 1964
663
16

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?
Marcel H A Muskiet, Mark M Smits, Linde M Morsink, Michaela Diamant. Nat Rev Nephrol 2014
112
16


Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses.
Gary A Herman, Cathy Stevens, Kristien Van Dyck, Arthur Bergman, Bingming Yi, Marina De Smet, Karen Snyder, Deborah Hilliard, Michael Tanen, Wesley Tanaka,[...]. Clin Pharmacol Ther 2005
356
16

Angiotensin II stimulates trafficking of NHE3, NaPi2, and associated proteins into the proximal tubule microvilli.
Anne D M Riquier-Brison, Patrick K K Leong, Kaarina Pihakaski-Maunsbach, Alicia A McDonough. Am J Physiol Renal Physiol 2010
54
16

DPP-4 inhibitors and lipids: systematic review and meta-analysis.
Matteo Monami, Caterina Lamanna, Carla Maria Desideri, Edoardo Mannucci. Adv Ther 2012
138
16

DPP4 inhibitors: a new approach in diabetes treatment.
John Doupis, Aristidis Veves. Adv Ther 2008
52
16

Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.
Renato O Crajoinas, Felipe T Oricchio, Thaissa D Pessoa, Bruna P M Pacheco, Lucília M A Lessa, Gerhard Malnic, Adriana C C Girardi. Am J Physiol Renal Physiol 2011
146
16

Stromal cell-derived factor-1 is upregulated by dipeptidyl peptidase-4 inhibition and has protective roles in progressive diabetic nephropathy.
Satoru Takashima, Hiroki Fujita, Hiromi Fujishima, Tatsunori Shimizu, Takehiro Sato, Tsukasa Morii, Katsushi Tsukiyama, Takuma Narita, Takamune Takahashi, Daniel J Drucker,[...]. Kidney Int 2016
56
16

Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.
Benjamin M Scirica, Eugene Braunwald, Itamar Raz, Matthew A Cavender, David A Morrow, Petr Jarolim, Jacob A Udell, Ofri Mosenzon, KyungAh Im, Amarachi A Umez-Eronini,[...]. Circulation 2014
392
16


Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
563
16

Protective effects of GLP-1 on glomerular endothelium and its inhibition by PKCβ activation in diabetes.
Akira Mima, Junko Hiraoka-Yamomoto, Qian Li, Munehiro Kitada, Chenzhong Li, Pedro Geraldes, Motonobu Matsumoto, Koji Mizutani, Kyoungmin Park, Christopher Cahill,[...]. Diabetes 2012
111
16



Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor.
Arthur J Bergman, Josee Cote, Bingming Yi, Thomas Marbury, Suzanne K Swan, William Smith, Keith Gottesdiener, John Wagner, Gary A Herman. Diabetes Care 2007
135
16


Managing diabetic patients with moderate or severe renal impairment using DPP-4 inhibitors: focus on vildagliptin.
Eleonora Russo, Giuseppe Penno, Stefano Del Prato. Diabetes Metab Syndr Obes 2013
23
16

Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats.
Wei Jing Liu, Shu Hua Xie, Yu Ning Liu, Won Kim, Heung Yong Jin, Sung Kwang Park, Yi Ming Shao, Tae Sun Park. J Pharmacol Exp Ther 2012
161
16


Microvasular and macrovascular complications in diabetes mellitus: Distinct or continuum?
Aastha Chawla, Rajeev Chawla, Shalini Jaggi. Indian J Endocrinol Metab 2016
272
16

Choosing a gliptin.
Vishal Gupta, Sanjay Kalra. Indian J Endocrinol Metab 2011
41
16

Mechanisms and pathways of anti-inflammatory activity of DPP-4 inhibitors in cardiovascular and renal protection.
Katarina Tomovic, Jelena Lazarevic, Gordana Kocic, Marina Deljanin-Ilic, Marko Anderluh, Andrija Smelcerovic. Med Res Rev 2019
18
16

Diabetes, hypertension, and chronic kidney disease progression: role of DPP4.
Ravi Nistala, Virginia Savin. Am J Physiol Renal Physiol 2017
33
16

Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.
M Tang-Christensen, P J Larsen, R Göke, A Fink-Jensen, D S Jessop, M Møller, S P Sheikh. Am J Physiol 1996
444
16


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.